All Posts By

Cardax

Astaxanthin for the Treatment of Osteoarthritis, a Large Unmet Medical Need

By | Science

By Timothy J. King, Ph.D., Vice President, Research Osteoarthritis (OA) is the most common form of arthritis, a chronic disease of aging. Effective and safe long-term treatment for most OA patients is not available, creating a large unmet medical need. The potential market for OA is very large, where it is estimated that more than 150 million middle class people globally suffer from OA. Symptomatic knee OA alone affects roughly 12% of persons 60 years…

Read More

Nutraceuticals as Pharmaceuticals: Disruptive New Therapeutics from Cardax

By | Management Insights | No Comments

By Gilbert Rishton, Ph.D., Cardax Chief Science Officer I accepted my position at Cardax as a seasoned veteran of the pharmaceutical industry. And, while my industry experience was indeed marked with satisfying projects, and even a successful drug launch with my former colleagues at Amgen, my most profound impression of modern drug development is in its epic failures. Particularly, the industry has failed to deliver the innovative new drugs that were to address society’s most…

Read More